DOES LOWERING SERUM-CHOLESTEROL LEVELS LOWER CORONARY HEART-DISEASE RISK

被引：12

作者：

ROSSOUW, JE ^{[1
]}

RIFKIND, BM ^{[1
]}

机构：

[1] NHLBI, LIPID METAB ATHEROGENESIS BRANCH, FED BLDG, ROOM 401, BETHESDA, MD 20892 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 1990年 / 19卷 / 02期

关键词：

D O I：

10.1016/S0889-8529(18)30325-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：279 / 297

页数：19

共 58 条

[51] CHOLESTEROL REDUCTION AND LIFE EXPECTANCY - A MODEL INCORPORATING MULTIPLE RISK-FACTORS [J].

TAYLOR, WC ;

PASS, TM ;

SHEPARD, DS ;

KOMAROFF, AL .

ANNALS OF INTERNAL MEDICINE, 1987, 106 (04) :605-614

[52] RISKS OF CANCER OF THE COLON AND RECTUM IN RELATION TO SERUM-CHOLESTEROL AND BETA-LIPOPROTEIN [J].

TORNBERG, SA ;

HOLM, LE ;

CARSTENSEN, JM ;

EKLUND, GA .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (26) :1629-1633

[53]

Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767

[54] REVIEW OF LIPID-LOWERING CLINICAL-TRIALS IN RELATION TO OBSERVATIONAL EPIDEMIOLOGIC STUDIES [J].

TYROLER, HA .

CIRCULATION, 1987, 76 (03) :515-522

[55]

WONG N D, 1989, Journal of the American College of Cardiology, V13, p37A

[56] OVERVIEW OF RESULTS OF RANDOMIZED CLINICAL-TRIALS IN HEART-DISEASE .2. UNSTABLE ANGINA, HEART-FAILURE, PRIMARY PREVENTION WITH ASPIRIN, AND RISK FACTOR MODIFICATION [J].

YUSUF, S ;

WITTES, J ;

FRIEDMAN, L .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (15) :2259-2263

[57]

1971, BRIT MED J, V4, P775

[58]

1987, JAMA-J AM MED ASSOC, V257, P937

← 1 2 3 4 5 6 →